All News

The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.

what we're reading logo

Senate and House Democrats again attempt to expand fertility treatments for veterans and active-duty personnel; CDC expects high hospitalization numbers due to “tripledemic” of COVID-19, respiratory syncytial virus, and the flu; a study found that MDMA, also known as ecstasy, can reduce posttraumatic stress disorder (PTSD) symptoms.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo